{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T17:34:08Z","timestamp":1792517648153,"version":"4.5.0"},"reference-count":48,"publisher":"American Society of Hematology","issue":"6","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,2,5]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>The use of posttransplant cyclophosphamide was initially pioneered as a means of permitting haploidentical transplantation across HLA barriers. This approach has now become a standard of care for the prevention of significant acute and chronic graft-versus-host disease (GVHD) after related and unrelated HLA-matched allogeneic peripheral blood stem cell transplant across a full spectrum of conditioning intensities. This article discusses recent advances, the mechanisms of action, and important unresolved questions in the prevention of GVHD that will help inform new prospective clinical studies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/blood.2025030416","type":"journal-article","created":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T17:38:31Z","timestamp":1766079511000},"page":"633-638","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":5,"title":["Posttransplant cyclophosphamide in HLA-matched peripheral blood transplantation: what\u2019s next?"],"prefix":"10.1182","volume":"147","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9497-0996","authenticated-orcid":false,"given":"David J.","family":"Curtis","sequence":"first","affiliation":[{"name":"1Clinical Haematology, Alfred Health, Melbourne, Australia"},{"name":"2Australian Centre for Blood Diseases, School of Translational Medicine, Monash University, Melbourne, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geoffrey R.","family":"Hill","sequence":"additional","affiliation":[{"name":"3Translational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"5","key":"2026051915413243000_bib1","first-page":"746","article-title":"The role of the spleen in radiation injury and recovery","volume":"35","author":"Jacobson","year":"1950","journal-title":"J Lab Clin Med"},{"issue":"1","key":"2026051915413243000_bib2","first-page":"197","article-title":"Modification of irradiation injury in mice and guinea pigs by bone marrow injections","volume":"12","author":"Lorenz","year":"1951","journal-title":"J Natl Cancer Inst"},{"issue":"4993","key":"2026051915413243000_bib3","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1136\/bmj.2.4993.626","article-title":"Treatment of murine leukaemia with x-rays and homologous bone marrow: preliminary communication","volume":"2","author":"Barnes","year":"1956","journal-title":"Br Med J"},{"issue":"1","key":"2026051915413243000_bib4","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1111\/j.1600-065X.1985.tb01160.x","article-title":"Graft-versus-host disease in dog and man: the Seattle experience","volume":"88","author":"Storb","year":"1985","journal-title":"Immunol Rev"},{"issue":"22","key":"2026051915413243000_bib5","doi-asserted-by":"crossref","first-page":"5074","DOI":"10.1200\/JCO.2005.09.020","article-title":"Allogeneic peripheral blood stem-cell compared with bone marrow transplantation in the management of hematologic malignancies: an individual patient data meta-analysis of nine randomized trials","volume":"23","author":"Stem Cell Trialists' Collaborative Group","year":"2005","journal-title":"J Clin Oncol"},{"issue":"2","key":"2026051915413243000_bib6","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1182\/blood-2002-08-2628","article-title":"Graft-versus-host disease after nonmyeloablative versus conventional hematopoietic stem cell transplantation","volume":"102","author":"Mielcarek","year":"2003","journal-title":"Blood"},{"issue":"8","key":"2026051915413243000_bib7","doi-asserted-by":"crossref","first-page":"2120","DOI":"10.1182\/blood.V78.8.2120.2120","article-title":"T-cell depletion of HLA-identical transplants in leukemia","volume":"78","author":"Marmont","year":"1991","journal-title":"Blood"},{"issue":"36","key":"2026051915413243000_bib8","doi-asserted-by":"crossref","first-page":"4003","DOI":"10.1200\/JCO.2017.75.8177","article-title":"Prospective, randomized, double-blind, phase III clinical trial of anti-T-lymphocyte globulin to assess impact on chronic graft-versus-host disease-free survival in patients undergoing HLA-matched unrelated myeloablative hematopoietic cell transplantation","volume":"35","author":"Soiffer","year":"2017","journal-title":"J Clin Oncol"},{"issue":"1","key":"2026051915413243000_bib9","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1056\/NEJMoa1506002","article-title":"Antilymphocyte globulin for prevention of chronic graft-versus-host disease","volume":"374","author":"Kr\u00f6ger","year":"2016","journal-title":"N Engl J Med"},{"issue":"9","key":"2026051915413243000_bib10","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/S1470-2045(09)70225-6","article-title":"Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial","volume":"10","author":"Finke","year":"2009","journal-title":"Lancet Oncol"},{"issue":"2","key":"2026051915413243000_bib11","doi-asserted-by":"crossref","first-page":"e100","DOI":"10.1016\/S2352-3026(19)30220-0","article-title":"Addition of anti-thymocyte globulin to standard graft-versus-host disease prophylaxis versus standard treatment alone in patients with haematological malignancies undergoing transplantation from unrelated donors: final analysis of a randomised, open-label, multicentre, phase 3 trial","volume":"7","author":"Walker","year":"2020","journal-title":"Lancet Haematol"},{"issue":"29","key":"2026051915413243000_bib12","doi-asserted-by":"crossref","first-page":"3367","DOI":"10.1200\/JCO.20.00150","article-title":"Antithymocyte globulin for matched sibling donor transplantation in patients with hematologic malignancies: a multicenter, open-label, randomized controlled study","volume":"38","author":"Chang","year":"2020","journal-title":"J Clin Oncol"},{"issue":"5023","key":"2026051915413243000_bib13","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1038\/209622a0","article-title":"19S and 17S antibody production in the cyclophosphamide- or methotrexate-treated rat","volume":"209","author":"Santos","year":"1966","journal-title":"Nature"},{"key":"2026051915413243000_bib14","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1038\/200084a0","article-title":"Prolongation of homograft survival in mice with single doses of cyclophosphamide","volume":"200","author":"Berenbaum","year":"1963","journal-title":"Nature"},{"issue":"5032","key":"2026051915413243000_bib15","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1038\/210139a0","article-title":"Production of graft-versus-host disease in the rat and its treatment with cytotoxic agents","volume":"210","author":"Santos","year":"1966","journal-title":"Nature"},{"issue":"4","key":"2026051915413243000_bib16","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1097\/00007890-197104000-00004","article-title":"The effect of cytotoxic drugs on graft-versus-host disease in mice","volume":"11","author":"Owens","year":"1971","journal-title":"Transplantation"},{"issue":"5","key":"2026051915413243000_bib17","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.4049\/jimmunol.146.5.1402","article-title":"Specific destruction of host-reactive mature T cells of donor origin prevents graft-versus-host disease in cyclophosphamide-induced tolerant mice","volume":"146","author":"Eto","year":"1991","journal-title":"J Immunol"},{"issue":"4","key":"2026051915413243000_bib18","first-page":"607","article-title":"HL-A-identical marrow transplants in aplastic anemia, acute leukemia, and lymphosarcoma employing cyclophosphamide","volume":"8","author":"Santos","year":"1976","journal-title":"Transpl Proc"},{"issue":"11","key":"2026051915413243000_bib19","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.1182\/blood-2009-06-225375","article-title":"High-dose cyclophosphamide for severe aplastic anemia: long-term follow-up","volume":"115","author":"Brodsky","year":"2010","journal-title":"Blood"},{"key":"2026051915413243000_bib20","doi-asserted-by":"crossref","first-page":"101034","DOI":"10.1016\/j.blre.2022.101034","article-title":"The development of post-transplant cyclophosphamide: Half a century of translational team science","volume":"62","author":"O'Donnell","year":"2023","journal-title":"Blood Rev"},{"issue":"11","key":"2026051915413243000_bib21","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1038\/nrclinonc.2009.146","article-title":"Cyclophosphamide and cancer: golden anniversary","volume":"6","author":"Emadi","year":"2009","journal-title":"Nat Rev Clin Oncol"},{"issue":"211","key":"2026051915413243000_bib22","doi-asserted-by":"crossref","first-page":"211ra157","DOI":"10.1126\/scitranslmed.3006960","article-title":"Aldehyde dehydrogenase expression drives human regulatory T cell resistance to posttransplantation cyclophosphamide","volume":"5","author":"Kanakry","year":"2013","journal-title":"Sci Transl Med"},{"issue":"13","key":"2026051915413243000_bib23","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1182\/blood-2013-10-525873","article-title":"Donor CD4+ Foxp3+ regulatory T cells are necessary for posttransplantation cyclophosphamide-mediated protection against GVHD in mice","volume":"124","author":"Ganguly","year":"2014","journal-title":"Blood"},{"issue":"76","key":"2026051915413243000_bib24","doi-asserted-by":"crossref","first-page":"eabo3420","DOI":"10.1126\/sciimmunol.abo3420","article-title":"Depletion of exhausted alloreactive T cells enables targeting of stem-like memory T cells to generate tumor-specific immunity","volume":"7","author":"Minnie","year":"2022","journal-title":"Sci Immunol"},{"issue":"6","key":"2026051915413243000_bib25","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1172\/JCI124218","article-title":"Post-transplantation cyclophosphamide prevents graft-versus-host disease by inducing alloreactive T cell dysfunction and suppression","volume":"129","author":"Wachsmuth","year":"2019","journal-title":"J Clin Invest"},{"issue":"11","key":"2026051915413243000_bib26","doi-asserted-by":"crossref","first-page":"e170125","DOI":"10.1172\/JCI170125","article-title":"Calcineurin inhibition rescues alloantigen-specific central memory T cell subsets that promote chronic GVHD","volume":"134","author":"Wang","year":"2024","journal-title":"J Clin Invest"},{"issue":"25","key":"2026051915413243000_bib27","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1056\/NEJMoa2215943","article-title":"Post-transplantation cyclophosphamide-based graft-versus-host disease prophylaxis","volume":"388","author":"Bola\u00f1os-Meade","year":"2023","journal-title":"N Engl J Med"},{"issue":"3","key":"2026051915413243000_bib28","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1056\/NEJMoa2503189","article-title":"Graft-versus-host disease prophylaxis with cyclophosphamide and cyclosporin","volume":"393","author":"Curtis","year":"2025","journal-title":"N Engl J Med"},{"issue":"11","key":"2026051915413243000_bib29","doi-asserted-by":"crossref","first-page":"3378","DOI":"10.1182\/bloodadvances.2021005847","article-title":"Posttransplant cyclophosphamide for prevention of graft-versus-host disease: results of the prospective randomized HOVON-96 trial","volume":"6","author":"Broers","year":"2022","journal-title":"Blood Adv"},{"issue":"33","key":"2026051915413243000_bib30","doi-asserted-by":"crossref","first-page":"3600","DOI":"10.1200\/JCO-25-01238","article-title":"Sirolimus and cyclosporine with post-transplant cyclophosphamide or mycophenolate mofetil as graft-versus-host disease prophylaxis in unrelated donor hematopoietic cell transplantation","volume":"43","author":"Ueda Oshima","year":"2025","journal-title":"J Clin Oncol"},{"issue":"4","key":"2026051915413243000_bib31","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1200\/JCO.21.02293","article-title":"Randomized phase III BMT CTN trial of calcineurin inhibitor-free chronic graft-versus-host disease interventions in myeloablative hematopoietic cell transplantation for hematologic malignancies","volume":"40","author":"Luznik","year":"2022","journal-title":"J Clin Oncol"},{"issue":"8","key":"2026051915413243000_bib32","first-page":"505","article-title":"Current activity trends and outcomes in hematopoietic cell transplantation and cellular therapy - a report from the CIBMTR","volume":"31","author":"Spellman","year":"2025","journal-title":"Transpl Cell Ther"},{"issue":"7","key":"2026051915413243000_bib33","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1158\/1078-0432.CCR-17-2148","article-title":"Flt-3L expansion of recipient CD8\u03b1+ dendritic cells deletes alloreactive donor T cells and represents an alternative to posttransplant cyclophosphamide for the prevention of GVHD","volume":"24","author":"Markey","year":"2018","journal-title":"Clin Cancer Res"},{"issue":"10","key":"2026051915413243000_bib34","doi-asserted-by":"crossref","first-page":"5291","DOI":"10.4049\/jimmunol.1301181","article-title":"Induced regulatory T cells promote tolerance when stabilized by rapamycin and IL-2 in vivo","volume":"191","author":"Zhang","year":"2013","journal-title":"J Immunol"},{"key":"2026051915413243000_bib35","doi-asserted-by":"crossref","first-page":"101093","DOI":"10.1016\/j.blre.2023.101093","article-title":"Relapse after allogeneic transplantation with post-transplant cyclophosphamide: shattering myths and evolving insight","volume":"62","author":"McCurdy","year":"2023","journal-title":"Blood Rev"},{"issue":"23","key":"2026051915413243000_bib36","doi-asserted-by":"crossref","first-page":"3291","DOI":"10.1182\/blood.2020009362","article-title":"Posttransplant cyclophosphamide is associated with increased cytomegalovirus infection: a CIBMTR analysis","volume":"137","author":"Goldsmith","year":"2021","journal-title":"Blood"},{"issue":"3","key":"2026051915413243000_bib37","first-page":"182.e1","article-title":"Incidence, risk factors, and outcomes of BK hemorrhagic cystitis in hematopoietic stem cell transplantation from HLA-matched and haploidentical donors with post-transplant cyclophosphamide","volume":"31","author":"Chorao","year":"2025","journal-title":"Transpl Cell Ther"},{"issue":"8","key":"2026051915413243000_bib38","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1182\/bloodadvances.2022009112","article-title":"Impact of GVHD prophylaxis on CMV reactivation and disease after HLA-matched peripheral blood stem cell transplantation","volume":"7","author":"Ueda Oshima","year":"2023","journal-title":"Blood Adv"},{"issue":"3","key":"2026051915413243000_bib39","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1007\/s00280-013-2232-8","article-title":"A pilot pharmacologic biomarker study in HLA-haploidentical hematopoietic cell transplant recipients","volume":"72","author":"Bemer","year":"2013","journal-title":"Cancer Chemother Pharmacol"},{"issue":"10","key":"2026051915413243000_bib40","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1016\/j.bbmt.2020.06.026","article-title":"Timing of post-transplantation cyclophosphamide administration in haploidentical transplantation: a comparative study on behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation","volume":"26","author":"Ruggeri","year":"2020","journal-title":"Biol Blood Marrow Transpl"},{"issue":"13","key":"2026051915413243000_bib41","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1182\/blood.2024026497","article-title":"Itacitinib for prevention of graft-versus-host disease and cytokine release syndrome in haploidentical transplantation","volume":"145","author":"Abboud","year":"2025","journal-title":"Blood"},{"issue":"16","key":"2026051915413243000_bib42","doi-asserted-by":"crossref","first-page":"4336","DOI":"10.1182\/bloodadvances.2024015094","article-title":"A prospective clinical trial of GVHD prophylaxis with post-transplant cyclophosphamide and abatacept","volume":"9","author":"Koura","year":"2025","journal-title":"Blood Adv"},{"issue":"1","key":"2026051915413243000_bib43","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1038\/s41408-024-00990-3","article-title":"Post-transplant cyclophosphamide versus anti-thymocyte globulin after reduced intensity peripheral blood allogeneic cell transplantation in recipients of matched sibling or 10\/10 HLA matched unrelated donors: final analysis of a randomized, open-label, multicenter, phase 2 trial","volume":"14","author":"Brissot","year":"2024","journal-title":"Blood Cancer J"},{"issue":"5","key":"2026051915413243000_bib44","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1038\/s41375-024-02225-7","article-title":"ATG or post-transplant cyclophosphamide to prevent GVHD in matched unrelated stem cell transplantation?","volume":"38","author":"Penack","year":"2024","journal-title":"Leukemia"},{"issue":"6","key":"2026051915413243000_bib45","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1038\/s41375-025-02619-1","article-title":"GVHD prophylaxis in matched related stem cell transplantation: why post-transplant cyclophosphamide can be recommended a study by the EBMT transplant complications working party","volume":"39","author":"Penack","year":"2025","journal-title":"Leukemia"},{"issue":"11","key":"2026051915413243000_bib46","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1200\/JCO.21.01755","article-title":"Naive T-cell depletion to prevent chronic graft-versus-host disease","volume":"40","author":"Bleakley","year":"2022","journal-title":"J Clin Oncol"},{"key":"2026051915413243000_bib47","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1038\/nm915","article-title":"CD4+CD25+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation","volume":"9","author":"Edinger","year":"2003","journal-title":"Nat Med"},{"issue":"18","key":"2026051915413243000_bib48","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1182\/blood.2024026446","article-title":"Donor regulatory T-cell therapy to prevent graft-versus-host disease","volume":"145","author":"Meyer","year":"2025","journal-title":"Blood"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/147\/6\/633\/2501563\/blood_bld-2025-030416-c-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/147\/6\/633\/2501563\/blood_bld-2025-030416-c-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T19:41:42Z","timestamp":1779219702000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/147\/6\/633\/557386\/Posttransplant-cyclophosphamide-in-HLA-matched"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,5]]},"references-count":48,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,2,5]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2025030416","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,2,5]]},"published":{"date-parts":[[2026,2,5]]}}}